FOLH1 and prostate cancer: PSMA is expressed in most types of prostate cancers, and its expression is enhanced in poorly differentiated, metastatic and hormone-refractory carcinomas, and hence it can be a valuable target for developing radiopharmaceutical and radiolabeled inhibitors, such as urea-based PSMA inhibitors, for precisely diagnosing, staging, and treating PCa [13,14].